
DT12 Rec'd PCT/PTO 18 FEB 2005



_			
	Attorney Docket	WATA-003	
ı	First Named Inventor	TAKEMORI, HIROSHI	
	International Application Number	PCT/JP2003/010535	
	Confirmation No.	Not yet assigned	
	Filing Date	Not yet assigned	
	Group Art Unit	Not yet assigned	
	Examiner Name	Not yet assigned	
	Title: "SALT-INDUC THEREOF"	CIBLE KINASE 2 AND USE	

Sir:

Address to: Mail Stop PCT

P.O. Box 1450

Commissioner for Patents

Alexandria, VA 22313-1450

INFORMATION
DISCLOSURE STATEMENT

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

Since each reference is on the order of hundreds of pages in length, for the convenience of the Office and the Examiner, the following references cited on form PTO SB/08A are provided as electronic copies on the CD-ROMs labeled "Copy 1" and "Copy 2":

WO 01/12659 A2; WO 00/73469 A2; and WO 01/81555 A2.

The undersigned hereby certifies that the contents of the CD-ROMs labeled "Copy 1" and "Copy 2" are identical.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 3 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. WATA-003 may be charged thereon.

By:

Date:

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303

bl 18,

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLI

Carol L. Francis

Registration No. 36,51

10/524979

DT12 Rec'd PCT/PTO 1 8 FEB 2085

Approved for U.S. Patent and Trademark Off

PTO/SB/08a (08-03) trough 07/31/2006. OMB 0651-0031 S. DEPARTMENT OF COMMERCE

Unde	r the Paperwork Reduction Act of	1995.	ersons are req	uired to respond to a collection of in	formation unle contains a valid OMB control number	
Substitute	e for form 1449A/PTO			Complete if Known		
				International Application	PCT/JP2003/010535	
	NFORMATION DISC	LOS	SURE	Filing Date	Not yet assigned	
	STATEMENT BY APPLICANT			First Named Inventor	TAKEMORI, HIROSHI	
				Art Unit	Not yet assigned	
	luca se manu chaote se no	2000	nvi	Examiner Name	Not yet assigned	
Sheet	1	of	2	Attorney Docket Number	WATA-003	

			U.S. PATENT (DOCUMENTS	
Examiner Initials'	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		WO 00/73469 A2	12/07/2000	Sugen Inc.	'		
		WO 01/12659 A2	02/22/2001	German Human Genome Project			
		WO 01/81555 A2	11/01/2001	Incyte Genomics Inc.			
					-		
						·	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Doi, et al., "Salt-inducible kinase represses cAMP-dependent protein kinase-mediated activation of human cholesterol side chain cleavage cytochrome P450 promoter through the CREB basic leucine zipper domain", The Journal of Biological Chemistry, vol. 277, no 18, issue of May 3, 2002, pp. 15629-15637	
		Feldman, et al., "The salt-inducible kinase, SIK, is induced by depolarization in brain", Journal of Neurochemistry, vol. 74, no. 6, (2000), pp. 2227-2238	
		Horike, et al., "Adipose-specific expression, phosphorylation of ser794 in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2", The Journal of Biological Chemistry, vol. 278, no. 20, May 16, 2003, pp. 18440-18447.	

Examiner	Date	
Signature_	 Consider	red

to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO

10/524979

DT12 Rec'd PCT/PTO/SB/08a &8-55EB 2005 Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Official S. DEPARTMENT OF COMMERCE

Unde	er the Paperwork Reduction Act of	199	ersons are re	guired to respond to a collection of ir	nformation un ontains a valid OMB control number.		
Substitute	bstitute for form 1449A/PTO			Complete if Known			
		MATION DISCLOSURE International Application PCT/JP2003/010535 Filing Date Not yet assigned	International Application	PCT/JP2003/010535			
	INFORMATION DISC						
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	CANT	First Named Inventor	TAKEMORI, HIROSHI			
		Art Unit	Not yet assigned				
	(ilea ae manu chaate ac na	rees	n/)	Examiner Name	Not yet assigned		
Sheet	2	of	2	Attorney Docket Number	WATA-003		

	Lin, et al., "Salt-inducible kinase is involved in the ACTH-cAMP-dependent protein kinase signaling in Y1 mouse adrenocortical tumor cells", Molecular Endocrinology (2001) 15(8), pp. 1264-1276.
	Mayr, et al., "Transcriptional regulation by the phosphorylation-dependent factor CREB", Nature Reviews, Molecular Cell Biology, vol. 2, August 2001, pp. 599-609.
	Reusch, et al., "CREB activation induces adipogenesis in 3T3-L cells", Molecular and cellular biology, Feb. 2000, pp. 1008-1020.
	Saltiel, et al., "Insulin signaling and the regulation of glucose and lipid metabolism", Nature vol. 414, December 13, 2001, pp. 799-806.
	Sul, et al., "Regulation of fat synthesis and adipose differentiation", progress in nucleic acid research and molecular biology, vol. 60, 1998, pp. 317-345.
	Tanasijevic, et al., "Phophorylation of the insulin receptor substrate IRS-1 by casein kinase II", The Journal of Biological Chemistry, vol. 268, no. 24, August 25, 1993, pp. 18157-18166.
	Wang, et al., "Cloning of a novel kinase (SIK) of the SNF1/AMPK family from high salt diet treated rat adrenal", FEBS letters 453, 1999, pp. 135-139
xaminer	Date

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Signature

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.